Results 61 to 70 of about 4,025 (198)

Clostridioides difficile Infection in an Italian Tertiary Care University Hospital: A Retrospective Analysis

Antibiotics, 2023
Clostridioides difficile infection (CDI) is a significant cause of morbidity and mortality, mostly in frail patients. Notification is not mandatory in Italy, and data on incidence, risk of death, and recurrence are lacking.
Alice Annalisa Medaglia, Alessandro Mancuso, Chiara Albano, Giuseppe Zinna, Luca Pipitò, Cinzia Calà, Rita Immordino, Raffaella Rubino, Silvia Bonura, Baldassare Canino, Giuseppe Calamusa, Claudia Colomba, Pier Luigi Almasio, Antonio Cascio   +13 more
doaj   +1 more source

Hypersensitivity Reactions Associated With Fidaxomicin Use [PDF]

Clinical Infectious Diseases, 2013
We report hypersensitivity reactions associated with fidaxomicin, an antibacterial drug approved for the treatment of Clostridium difficile-associated diarrhea. These reactions are viewed as significant because of severity and unexpected because fidaxomicin is minimally absorbed.
Dmitri E, Iarikov, John, Alexander, Sumathi, Nambiar   +2 more
openaire   +2 more sources

Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub‐Types

Biotechnology and Bioengineering, Volume 123, Issue 2, Page 310-323, February 2026.
ABSTRACT Clostridioides difficile infection presents an escalating clinical challenge due to the proliferation of hypervirulent and antibiotic‐resistant strains. The primary symptoms of disease, namely colitis and diarrhea, are induced by the release of two toxins: TcdA and TcdB.
Carly M. Catella, Sudeep Sarma, Caroline M. Hinesley, Corey E. Febo, Keith A. Breau, Deniz Durmusoglu, Ethan Purnell, Scott T. Magness, Carol K. Hall, Stefano Menegatti, Nathan Crook   +10 more
wiley   +1 more source

In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile

, 2023
International audienceBackground : Fidaxomicin is a first-line treatment for Clostridioides difficile infections (CDIs). Fidaxomicin resistance has rarely been reported in this urgent antimicrobial resistance threat as defined by the CDC. Objectives : To
Gaëtan Poulen, Barbut, Frédéric, Mark Wilcox, Cyril Anjou, Hélène Marchandin, Jane Freeman, Poulen, Gaëtan, Freeman, Jane, Frédéric Barbut, Wilcox, Mark, Anjou, Cyril, Hélène Jean-Pierre, Marchandin, Hélène, Jean-Pierre, Hélène   +13 more
core   +1 more source

Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating Clostridioides difficile Infection and the Associated Recurrence Rate: A Retrospective Cohort Study

Antibiotics, 2023
Clostridioides difficile infection (CDI) has significant implications for healthcare economics. Although clinical trials have compared fidaxomicin (FDX) and vancomycin, comparisons of FDX and oral metronidazole (MNZ) are limited.
Nobuaki Mori, Jun Hirai, Wataru Ohashi, Nobuhiro Asai, Yuichi Shibata, Hiroshige Mikamo   +5 more
doaj   +1 more source

Oral proton‐reprogrammed nanomedicine to break the inflammatory bowel disease‐Clostridium difficile infection vicious cycle

iMeta, Volume 5, Issue 1, February 2026.
Research on the mechanism of OPR restoring intestinal epithelial cell (IEC) structure and function in inflammatory bowel disease (IBD) treatment. (A) Schematic diagram of OPR structure and the rate of GP release under different conditions. (B) Schematic diagram of OPR targeting IBD colonic lesions through charge interaction.
Wensheng Chen, Yuntao Zhang, Jue Wang, Yiming Li, Hao Wu, Qiong Huang, Wei Wu, Kelong Ai   +7 more
wiley   +1 more source

Improving Clinical Outcomes of Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection Through Empirical Donor Selection and Optimised Dosing: A Quality Improvement Study

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 2, Page 276-287, January 2026.
In a large‐scale, multiple‐site Danish faecal microbiota transplantation (FMT) system, the cure rates in patients with Clostridioides difficile infection treated with encapsulated FMT were improved following exclusion of three low‐performing donors and implementation of a two‐dose FMT regimen.
Sara Ellegaard Paaske, Simon Mark Dahl Baunwall, Tone Rubak, Nina Rågård, Jens Kelsen, Mette Mejlby Hansen, Anders Bergh Lødrup, Søren Lyhne, Emilie Glavind, Christa Marie Culmback Fernis, Stine Hald, Lise Tornvig Erikstrup, Lars Vinter‐Jensen, Simon Lal, Susan Mikkelsen, Christian Erikstrup, Jens Frederik Dahlerup, Christian Lodberg Hvas   +17 more
wiley   +1 more source

Gut Microbiome as a Source and Propagator of Multidrug‐Resistance: Mechanisms and Therapeutic Strategies

Advanced Gut &Microbiome Research, Volume 2026, Issue 1, 2026.
Human gut microbiome has risen as a critical nexus in the global landscape of antimicrobial resistance (AMR), acting both as a reservoir and a driver of multidrug‐resistant organisms (MDROs). This review explores the mechanistic foundations by which the gut microbiota contributes to resistance development, focusing on the acquisition and spread of ...
Meghana Shashikanth, D. B. M. Virupakshaiah, Jiong Yu   +2 more
wiley   +1 more source

Case Commentary: Emergence of clinically relevant fidaxomicin-resistant Clostridioides difficile strains

Antimicrobial Agents and Chemotherapy
Clostridioides difficile infection (CDI) has limited antibiotic treatment options, with fidaxomicin being the guideline-preferred antibiotic. C. E. Kaple, S. N. Redmond, J. L. Cadum, B. Hausman, et al.
Kevin W. Garey, Julian G. Hurdle
doaj   +1 more source

Management of Clostridium difficile in a developing nation

Archives of Pharmacy Practice, 2016
Introduction: Clostridium difficile is the most important definable cause of healthcare acquired diarrhea. Recommended treatments for Clostridium difficile infection (CDI) are metronidazole, oral vancomycin and fidaxomicin (a new narrow spectrum ...
Azadeh Nasrollah, Shiva Hashemi, Parvin Talebloo, Mehdi Rajabi, Syed Azhar Syed Sulaiman, Usman Abubakar   +5 more
doaj   +1 more source